Erickson Michael G, Executive Vice President at IDEXX Laboratories (IDXX), has demonstrated a clear selling bias in recent transactions, with $4.46 million in total sales outweighing $1.57 million in purchases across 42 reported trades. All activity has been concentrated in IDXX shares, with no diversification into other securities. The most notable transactions occurred in February 2026, when Erickson executed multiple large sales totaling approximately $3.1 million across February 17 and 19. The largest single transaction was a $1.69 million sale on February 17, followed by an $806,618 disposition the same day. These were accompanied by smaller sales ranging from $25,195 to $433,443. While the filings show some acquisition activity—including a $612,987 purchase on February 14, 2026, and multiple smaller buys—the overall pattern skews heavily toward divestment. The most recent nine transactions were all sales, with no buys recorded since mid-February 2026. Earlier activity includes a $206,697 sale in August 2025 and smaller dispositions, suggesting a consistent trend of reducing exposure to IDXX equity over time. The transactions appear to be methodical rather than opportunistic, with multiple same-day trades at varying sizes, potentially indicating structured selling plans or portfolio rebalancing.
AI-assisted summary